Denmark Ditches J&J COVID Vaccine, Says Benefits ‘Do Not Outweigh Risk’ of Blood Clots

Denmark on Monday became the first country to exclude Johnson & Johnson’s (J&J) COVID vaccine from its vaccination program over a potential link to blood clotting disorders.The Danish Health Authority said in a statement it had concluded “the benefits of using the COVID-19 vaccine from J&J do not outweigh the risk of causing the possible adverse effect in those who receive the vaccine,” Reuters reported.

Danish health officials noted the European Medicines Agency’s (EMA) conclusion that “there is a possible link between rare but severe cases of blood clots and the COVID-19 vaccine from J&J,” referring to an investigation last month into eight U.S. reports of rare blood clots — one of which was fatal — that occurred after recent vaccination.

Unlike the Danish Health Authority however, the EMA concluded the benefits of using the J&J vaccine outweigh the risks. The EMA did recommend adding a warning to J&J’s vaccine label, and the company said it would comply with that measure.

“Taking the present situation in Denmark into account, what we are currently losing in our effort to prevent severe illness from COVID-19 cannot outweigh the risk of causing possible side effects in the form of severe blood clots in those we vaccinate,” the health authority said.

Denmark stopped using AstraZeneca’s vaccine last month after European regulators found a possible link between AstraZeneca’s COVID vaccine and “very rare” blood clots.

Both J&J and AstraZeneca vaccines use a modified adenovirus vector technology as opposed to the mRNA technology used in the Moderna and Pfizer’s COVID vaccines.

Though J&J and AstraZeneca vaccines have been under the microscope for their potential to cause blood clots, scientists warned, as far back as December 2020, that mRNA vaccines like Pfizer and Moderna pose similar risks.

Continued at link.

FDA Issues Warning for Covid Vaccine Due to 'Blood Clot Risk,' Restricts It to Adults 18 Years & Older

The Food and Drug Administration has issued new restrictions on the single-shot Johnson & Johnson Covid vaccine.

The Johnson & Johnson shots are now limited to adults 18 years and older or for whom other COVID-19 vaccines are deemed not accessible or clinically appropriate due to the risk of blood clots.

"The FDA said its analysis had determined that the risk of thrombosis with thrombocytopenia syndrome after the administration of the shot warrants limiting of the authorization," CNBC reported.

"We recognize that the Janssen COVID-19 Vaccine still has a role in the current pandemic response in the United States and across the global community," said Peter Marks, director of the FDA's Center for Biologics Evaluation and Research. "Our action reflects our updated analysis of the risk of TTS following administration of this vaccine and limits the use of the vaccine to certain individuals.”

The FDA had confirmed 60 cases, including 9 deaths, of the “rare but serious” blood clotting condition.

"The FDA temporarily paused the administration of the Johnson & Johnson COVID-19 vaccine last year after several reported cases of blood clotting," UPI News noted. "At the time, all six cases were found in women between the ages of 18 and 48. At least one died."

It is not the only serious side effect of Covid vaccines that has been verified this week. An MIT study found that there was an increased risk of side effects among 16-39 year-olds in Israel.

"COVID-19 vaccination was 'significantly associated' with a 25% jump in emergency medical services (EMS) for heart problems in 16-39 year-olds in Israel, whose vaccination rate is among the world's highest, according to a peer-reviewed study by MIT researchers," Just the News reported.

"While not establishing causal relationships, the findings raise concerns regarding vaccine-induced undetected severe cardiovascular side-effects and underscore the already established causal relationship between vaccines and myocarditis, a frequent cause of unexpected cardiac arrest in young individuals," the study says.

In October 2021, some European countries suspended authorization for Moderna vaccines due to the increased risk of heart inflammation for young persons.

"Scandinavian authorities on Wednesday suspended or discouraged the use of Moderna’s COVID-19 vaccine in young people because of an increased risk of heart inflammation, a very rare side effect associated with the shot," Fox reported at the time.

"Sweden suspended the use of Moderna for those recipients under 30, Denmark said those under 18 won’t be offered the Swiss-made vaccine, and Norway urged those under 30 to get the Pfizer vaccine instead," the report added.